tiprankstipranks
Trending News
More News >
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
US Market

PROCEPT BioRobotics (PRCT) Stock Forecast & Price Target

Compare
653 Followers
See the Price Targets and Ratings of:

PRCT Analyst Ratings

Moderate Buy
9Ratings
Moderate Buy
6 Buy
2 Hold
1 Sell
Based on 9 analysts giving stock ratings to
PROCEPT
BioRobotics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRCT Stock 12 Month Forecast

Average Price Target

$33.71
▲(28.37% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for PROCEPT BioRobotics in the last 3 months. The average price target is $33.71 with a high forecast of $60.00 and a low forecast of $20.00. The average price target represents a 28.37% change from the last price of $26.26.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","42":"$42","65":"$65","30.5":"$30.5","53.5":"$53.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,30.5,42,53.5,65],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.9,28.52307692307692,31.146153846153844,33.76923076923077,36.39230769230769,39.01538461538461,41.63846153846154,44.261538461538464,46.88461538461539,49.50769230769231,52.13076923076923,54.753846153846155,57.37692307692308,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.9,26.50076923076923,27.10153846153846,27.70230769230769,28.303076923076922,28.903846153846153,29.504615384615384,30.105384615384615,30.706153846153846,31.306923076923077,31.907692307692308,32.50846153846154,33.10923076923077,{"y":33.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.9,25.446153846153845,24.99230769230769,24.538461538461537,24.084615384615383,23.63076923076923,23.176923076923075,22.723076923076924,22.26923076923077,21.815384615384616,21.361538461538462,20.907692307692308,20.453846153846154,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":64.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.46,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.14,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$60.00Average Price Target$33.71Lowest Price Target$20.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on PRCT
Truist Financial
Truist Financial
$47$30
Buy
14.24%
Upside
Reiterated
03/02/26
PROCEPT BioRobotics (PRCT) Gets a Buy from Truist Financial
UBS
$62$30
Buy
14.24%
Upside
Reiterated
03/02/26
Procept BioRobotics price target lowered to $30 from $62 at UBSProcept BioRobotics price target lowered to $30 from $62 at UBS
Piper Sandler Analyst forecast on PRCT
Piper Sandler
Piper Sandler
$28
Buy
6.63%
Upside
Reiterated
03/02/26
Piper Sandler Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)
Bank of America Securities Analyst forecast on PRCT
Bank of America Securities
Bank of America Securities
$20
Sell
-23.84%
Downside
Reiterated
02/27/26
Procept BioRobotics downgraded to Underperform from Neutral at BofAProcept BioRobotics downgraded to Underperform from Neutral at BofA
Oppenheimer Analyst forecast on PRCT
Oppenheimer
Oppenheimer
$60
Hold
128.48%
Upside
Downgraded
02/26/26
Procept BioRobotics downgraded to Perform from Outperform at OppenheimerProcept BioRobotics downgraded to Perform from Outperform at Oppenheimer
TD Cowen
$50$34
Buy
29.47%
Upside
Reiterated
02/26/26
PROCEPT BioRobotics: Commercial Reset Creates Near-Term Headwinds but Strengthens Long-Term Buy Thesis
William Blair Analyst forecast on PRCT
William Blair
William Blair
Buy
Reiterated
02/26/26
Buy Rating on Aquablation Developer: Short-Term Execution Headwinds Masking Long-Term Medtech Upside
BTIG
Hold
Reiterated
02/26/26
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (NASDAQ: PRCT), Soleno Therapeutics (NASDAQ: SLNO) and Agilent (NYSE: A)
Wells Fargo Analyst forecast on PRCT
Wells Fargo
Wells Fargo
$51$34
Buy
29.47%
Upside
Reiterated
02/26/26
Procept BioRobotics price target lowered to $34 from $51 at Wells FargoProcept BioRobotics price target lowered to $34 from $51 at Wells Fargo
Morgan Stanley Analyst forecast on PRCT
Morgan Stanley
Morgan Stanley
$56$51
Buy
94.21%
Upside
Reiterated
12/02/25
Procept BioRobotics price target lowered to $51 from $56 at Morgan StanleyProcept BioRobotics price target lowered to $51 from $56 at Morgan Stanley
Leerink Partners Analyst forecast on PRCT
Leerink Partners
Leerink Partners
$83$65
Buy
147.52%
Upside
Reiterated
10/14/25
PROCEPT BioRobotics (PRCT) Gets a Buy from Leerink Partners
Stephens
$70
Buy
166.57%
Upside
Initiated
07/09/25
Procept BioRobotics initiated with an Overweight at StephensProcept BioRobotics initiated with an Overweight at Stephens
Jefferies
Hold
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Intuitive Surgical (NASDAQ: ISRG) and Bio-Rad Laboratories (NYSE: BIO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on PRCT
Truist Financial
Truist Financial
$47$30
Buy
14.24%
Upside
Reiterated
03/02/26
PROCEPT BioRobotics (PRCT) Gets a Buy from Truist Financial
UBS
$62$30
Buy
14.24%
Upside
Reiterated
03/02/26
Procept BioRobotics price target lowered to $30 from $62 at UBSProcept BioRobotics price target lowered to $30 from $62 at UBS
Piper Sandler Analyst forecast on PRCT
Piper Sandler
Piper Sandler
$28
Buy
6.63%
Upside
Reiterated
03/02/26
Piper Sandler Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)
Bank of America Securities Analyst forecast on PRCT
Bank of America Securities
Bank of America Securities
$20
Sell
-23.84%
Downside
Reiterated
02/27/26
Procept BioRobotics downgraded to Underperform from Neutral at BofAProcept BioRobotics downgraded to Underperform from Neutral at BofA
Oppenheimer Analyst forecast on PRCT
Oppenheimer
Oppenheimer
$60
Hold
128.48%
Upside
Downgraded
02/26/26
Procept BioRobotics downgraded to Perform from Outperform at OppenheimerProcept BioRobotics downgraded to Perform from Outperform at Oppenheimer
TD Cowen
$50$34
Buy
29.47%
Upside
Reiterated
02/26/26
PROCEPT BioRobotics: Commercial Reset Creates Near-Term Headwinds but Strengthens Long-Term Buy Thesis
William Blair Analyst forecast on PRCT
William Blair
William Blair
Buy
Reiterated
02/26/26
Buy Rating on Aquablation Developer: Short-Term Execution Headwinds Masking Long-Term Medtech Upside
BTIG
Hold
Reiterated
02/26/26
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (NASDAQ: PRCT), Soleno Therapeutics (NASDAQ: SLNO) and Agilent (NYSE: A)
Wells Fargo Analyst forecast on PRCT
Wells Fargo
Wells Fargo
$51$34
Buy
29.47%
Upside
Reiterated
02/26/26
Procept BioRobotics price target lowered to $34 from $51 at Wells FargoProcept BioRobotics price target lowered to $34 from $51 at Wells Fargo
Morgan Stanley Analyst forecast on PRCT
Morgan Stanley
Morgan Stanley
$56$51
Buy
94.21%
Upside
Reiterated
12/02/25
Procept BioRobotics price target lowered to $51 from $56 at Morgan StanleyProcept BioRobotics price target lowered to $51 from $56 at Morgan Stanley
Leerink Partners Analyst forecast on PRCT
Leerink Partners
Leerink Partners
$83$65
Buy
147.52%
Upside
Reiterated
10/14/25
PROCEPT BioRobotics (PRCT) Gets a Buy from Leerink Partners
Stephens
$70
Buy
166.57%
Upside
Initiated
07/09/25
Procept BioRobotics initiated with an Overweight at StephensProcept BioRobotics initiated with an Overweight at Stephens
Jefferies
Hold
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Intuitive Surgical (NASDAQ: ISRG) and Bio-Rad Laboratories (NYSE: BIO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PROCEPT BioRobotics

3 Months
xxx
Success Rate
13/21 ratings generated profit
62%
Average Return
+3.13%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +3.13% per trade.
1 Year
Richard NewitterTruist Financial
Success Rate
13/29 ratings generated profit
45%
Average Return
+15.03%
reiterated a buy rating 4 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 44.83% of your transactions generating a profit, with an average return of +15.03% per trade.
2 Years
xxx
Success Rate
8/21 ratings generated profit
38%
Average Return
-2.07%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 38.10% of your transactions generating a profit, with an average return of -2.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRCT Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
8
9
8
2
0
Buy
4
6
4
8
9
Hold
35
30
20
11
10
Sell
1
1
1
1
1
Strong Sell
0
0
0
0
0
total
48
46
33
22
20
In the current month, PRCT has received 9 Buy Ratings, 10 Hold Ratings, and 1 Sell Ratings. PRCT average Analyst price target in the past 3 months is 33.71.
Each month's total comprises the sum of three months' worth of ratings.

PRCT Financial Forecast

PRCT Earnings Forecast

Next quarter’s earnings estimate for PRCT is -$0.53 with a range of -$0.61 to -$0.11. The previous quarter’s EPS was -$0.53. PRCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.
Next quarter’s earnings estimate for PRCT is -$0.53 with a range of -$0.61 to -$0.11. The previous quarter’s EPS was -$0.53. PRCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.

PRCT Sales Forecast

Next quarter’s sales forecast for PRCT is $80.67M with a range of $79.06M to $82.43M. The previous quarter’s sales results were $76.38M. PRCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.
Next quarter’s sales forecast for PRCT is $80.67M with a range of $79.06M to $82.43M. The previous quarter’s sales results were $76.38M. PRCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.

PRCT Stock Forecast FAQ

What is PRCT’s average 12-month price target, according to analysts?
Based on analyst ratings, PROCEPT BioRobotics’s 12-month average price target is 33.71.
    What is PRCT’s upside potential, based on the analysts’ average price target?
    PROCEPT BioRobotics has 28.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRCT a Buy, Sell or Hold?
          PROCEPT BioRobotics has a consensus rating of Moderate Buy which is based on 6 buy ratings, 2 hold ratings and 1 sell ratings.
            What is PROCEPT BioRobotics’s price target?
            The average price target for PROCEPT BioRobotics is 33.71. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $60.00 ,the lowest forecast is $20.00. The average price target represents 28.37% Increase from the current price of $26.26.
              What do analysts say about PROCEPT BioRobotics?
              PROCEPT BioRobotics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of PRCT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.